TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
BIIB

Biogen Inc.

Healthcare · Drug Manufacturers - General

215.50$ -1.6% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

Biogen Inc. (BIIB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 2,736 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement BIIB
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
2,530 2,386 2,291 2,465 2,466 2,455 2,431 2,646 2,455 2,279 2,478 2,736 9,948
660 618 498 956 639 584 578 946 877 496 661 1,179 3,213
1,871 1,768 1,792 1,509 1,827 1,871 1,853 1,699 1,578 1,783 1,817 1,557 6,735
797 648 524 592 673 684 546 530 370 509 573 496 1,947
788 537 582 554 588 612 573 584 595 683 607 710 2,595
1,550 1,256 1,102 1,143 1,250 1,362 1,121 1,111 964 1,840 1,419 1,239 5,463
321 512 690 367 577 509 733 588 614 -57 397 318 1,272
64 72 69 61 60 60 60 73 67 68 68 82 285
-141 292 465 699 451 292 311 744 557 -211 378 132 856
-73 43 71 115 63 25 71 109 91 -163 58 35 21
-68 250 393 584 389 267 241 635 467 -48 320 98 835
396 601 780 968 714 692 865 1,110 827 212 554 78 1,671

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?